LGND: Yeah, the cash to mkt cap ratio is pretty amazing for a company that generates decent earnings. You typically see that in companies that haven't sniffed a positive EPS.
I have a personal experience (grandfather) with the deleterious effects of contrast agents, given our healthcare system's overuse of imaging (since it's incented). He had kidney impairment due to multiple administrations of contrast agent over the years. Had a fall off a ladder, broken elbow and pelvis, emergency room docs imaged for bleeds. Would have recovered if non-damaging contrast agent available years earlier or doc's had held off on contrast that time. Ended up in ICU for kidneys, eventually on dialysis, infection, gone.
Stock bounced off upper 80's back in 2015/16 and has never been that low since. Seems to earn double what it did back then, too.
I forgot to ask the board last time if anyone knew this Lemelson Capital that seems to have an axe to grind with LGND. Checked out their website and "unprofessional" is the nicest way I can describe them.
